RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials

RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials. The goal of these services is to stretch project funds further, ensuring greater impact and cost savings. Below is the list of subsidized services offered:

 

100% Subsidized Services (RareKids-CAN will cover 100% of the cost of the following services):

    • Consultations: We will conduct a robust consultation to identify areas of needs for your project with valuable involvement from relevant sub platforms based on your project needs to ensure your project receives adequate support.
    • High-level project management: An experienced project manager will ensure efficient coordination, oversight, and successful execution from inception to completion for your clinical trial.
    • Database build (not including management): We will provide project-specific electronic case report form (e-CRF) development and database management in a validated REDCap database housed at the Women and Children’s Health Research Institute (WCHRI).
    • Data Safety Monitoring Board: From our repository of individuals with specific expertise relevant to your project, we facilitate a centralized data safety monitoring board to ensure participant safety and provide expertise on clinical trial conduct for continuation, modification, or termination.

 

50% Subsidized Services (RareKids-CAN will cover 50% of the total cost of the following services):

    • Regulatory submissions: We assist study teams in the preparation and submission of clinical trial applications, investigational testing authorizations, and single-patient study applications for regulated clinical trials to Health Canada. We will also assist in adverse event reporting.
    • Monitoring: We have a dedicated and experienced monitoring team to perform risk-based remote and on-site monitoring to meet the Health Canada required sponsor obligations.

All other services are 100% cost recovered (i.e., RareKids-CAN will not subsidize)

 

If you have a clinical trial that require these services or would like to further discuss, you can complete the project intake form.

Read next...

CPNG 2026

Zolgensma® Safety Update and CPNG Guidance for Families

The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.

2026 Trainee Publication of the Year Awardee Spotlight on Jules Granet

Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee

Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.

Save the date: 8th Ottawa International Conference On Neuromuscular Disease & Biology

Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology

We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.